Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates

International Journal of Antimicrobial Agents

Volumn 35, Issue 6, 2010, Pages 537-543

  Farrell, David J ^a   Sader, Helio S ^a   Castanheira, Mariana ^a   Biedenbach, Douglas J ^a   Rhomberg, Paul R ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; CEM 101; Community acquired bacterial pneumonia; Ketolide; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFDINIR; CEM 101; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEMOLYTIC STREPTOCOCCUS; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; TRIAZOLES;

EID: 77951769604     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.01.026     Document Type: Article

References (37)

1. World Health Organization. Acute respiratory infections (update September 2009). Geneva, Switzerland, WHO. [accessed 10 February 2010]. http://www.who.int/vaccine_research/diseases/ari/en/index.html.
2. File T.M. The epidemiology of respiratory tract infections. Semin Respir Infect 2000, 15:184-194.
3. Bartlett J.G. Is activity against 'atypical' pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis 2008, 47(Suppl. 3):S232-S236.
4. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl. 2):S27-S72.
5. Felmingham D., Grüneberg R.N. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000, 45:191-203. Alexander Project Group.
6. Hoban D., Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002, 50(Suppl. S1):49-59.
7. Jacobs M.R. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr Infect Dis J 2003, 22(8 Suppl.):S109-S119.
8. Jacobs M.R., Koornhof H.J., Robins-Browne R.M., Stevenson C.M., Vermaak Z.A., Freiman I., et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978, 299:735-740.
9. Breiman R.F., Butler J.C., Tenover F.C., Elliott J.A., Facklam R.R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994, 271:1831-1835.
10. Doern G.V., Brueggemann A., Holley H.P., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996, 40:1208-1213.
11. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
12. Farrell D.J., Morrissey I., Bakker S., Morris L., Buckridge S., Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol 2004, 42:764-768.
13. Pelton S.I., Huot H., Finkelstein J.A., Bishop C.J., Hsu K.K., Kellenberg J., et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:468-472.
14. Farrell D.J., Klugman K.P., Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007, 26:123-128.
15. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009, 15(Suppl. 3):16-20.
16. Jenkins S.G., Farrell D.J. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009, 15:1260-1264.
17. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Lexau C., Reingold A., et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924.
18. Daneman N., McGeer A., Green K., Low D.E. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006, 43:432-438. Toronto Invasive Bacterial Diseases Network.
19. Ackermann G., Rodloff A.C. Drugs of the 21st century: telithromycin (HMR 3647)-the first ketolide. J Antimicrob Chemother 2003, 51:497-511.
20. Drugs RD. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs RD 2007; 8:95-102.
21. Wierzbowski A.K., Karlowsky J.A., Hoban D.J., Zhanel G.G. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). J Antimicrob Chemother 2009, 63:620-622.
22. Jones R.N., Biedenbach D.J., Rhomberg P.R., Fritsche T.R., Sader H.S. Antimicrobial characterization of CEM-101 activity against 331 respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A (MDR-19A) isolates. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract F1-3975].
23. McGhee P., Nagai K., Appelbaum P.C. Activity of CEM-101 compared to other agents against macrolide-susceptible and resistant streptococci. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract F1-3974].
24. Roblin P.M., Kohlhoff S.A., Hammerschlag M.R. In vitro activity of CEM 101, a new ketolide antibiotic against Chlamydia trachomatis and Chlamydia pneumoniae. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington, DC 2008, ASM Press, Washington, DC, [Abstract F1-3978].
25. Lemaire S., Van Bambeke F., Tulkens P.M. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, towards Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 2009, 53:3734-3743.
26. Waites K.B., Crabb D.M., Duffy L.B. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009, 53:2139-2141.
27. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M7-A8. Wayne, PA: CLSI; 2009.
28. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
29. Marco F., Biedenbach D.J., Jones R.N. Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. Diagn Microbiol Infect Dis 1997, 28:55-57.
30. Li X., Atkinson T.P., Hagood J., Makris C., Duffy L.B., Waites K.B. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009, 28:693-696.
31. Hidron A.I., Low C.E., Honig E.G., Blumberg H.M. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009, 9:384-392.
32. Critchley I.A., Brown S.D., Traczewski M.M., Tillotson G.S., Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. faropenem surveillance study. Antimicrob Agents Chemother 2007, 51:4382-4389.
33. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002, 34:482-492.
34. Champney W.S., Mentens N., Zurawick K. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol 2004, 49:239-247.
35. Farrell D.J., Shackcloth J., Barbadora K.A., Green M.D. Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations. Antimicrob Agents Chemother 2006, 50:817-818.
36. Santos J.W., Nascimento D.Z., Guerra V.A., Rigo Vda S., Michel G.T., Dalcin T.C. Community-acquired staphylococcal pneumonia. J Bras Pneumol 2008, 34:683-689.
37. Jones R., Sader H., Biedenbach D. Antimicrobial characterization of CEM-101: activity against staphylococci, beta-haemolytic and viridians group streptococci. Abstracts of the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 16-19 May 2009, Helsinki, Finland 2009, ESCMID, Basel, Switzerland.